Tom 15, Nr 4 (2022)
Artykuł przeglądowy
Opublikowany online: 2022-12-30
Wyświetlenia strony
665
Wyświetlenia/pobrania artykułu
380
Inhibitory czynnika XI — przełom w profilaktyce i leczeniu przeciwzakrzepowym?
Journal of Transfusion Medicine 2022;15(4):324-328.
Streszczenie
Dostępna farmakologiczna profilaktyka przeciwzakrzepowa wiąże się z małym, ale dostrzegalnym
ryzykiem krwawienia, dlatego poszukuje się leków, które chroniłyby przed zakrzepicą,
nie zwiększając istotnie ryzyka krwawienia. Takimi lekami wydają się inhibitory czynnika
XI. W artykule omówiono dotychczasowe badania kliniczne nad zastosowaniem inhibitorów
czynnika XI w profilaktyce żylnej choroby zakrzepowo-zatorowej i zakrzepicy tętniczej.
Słowa kluczowe: profilaktyka przeciwzakrzepoważylna choroba zakrzepowo-zatorowazakrzepica tętniczainhibitory czynnika XIwymiana stawu kolanowegowymiana stawu biodrowego
Referencje
- Zapata-Wainberg G, Ximénez-Carrillo Rico Á, Benavente Fernández L, et al. representing the research team of the TAC Registry study. Epidemiology of intracranial haemorrhages associated with vitamin K antagonist oral anticoagulants in spain: TAC registry. Interv Neurol. 2015; 4(1-2): 52–58.
- Khan F, Tritschler T, Kahn S, et al. Venous thromboembolism. Lancet. 2021; 398(10294): 64–77.
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383(9921): 955–962.
- van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014; 124(12): 1968–1975.
- Plow EF, Wang Y, Simon DI. The search for new antithrombotic mechanisms and therapies that may spare hemostasis. Blood. 2018; 131(17): 1899–1902.
- Hsu C, Hutt E, Bloomfield D, et al. Factor XI Inhibition to Uncouple Thrombosis From Hemostasis. J Am Coll Cardiol. 2021; 78(6): 625–631.
- Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013; 39(6): 621–631.
- Weitz JI, Fredenburgh JC. 2017 scientific sessions sol sherry distinguished lecture in thrombosis: factor XI as a target for new anticoagulants. Arterioscler Thromb Vasc Biol. 2018; 38(2): 304–310.
- Büller HR, Bethune C, Bhanot S, et al. FXI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015; 372(3): 232–240.
- Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020; 323(2): 130–139.
- Verhamme P, Yi BA, Segers A, et al. ANT-005 TKA Investigators. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021; 385(7): 609–617.
- Weitz JI, Strony J, Ageno W, et al. AXIOMATIC-TKR Investigators. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021; 385(23): 2161–2172.
- Presume J, Ferreira J, Ribeiras R, et al. Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery-Systematic review and meta-analysis. J Thromb Haemost. 2022; 20(12): 2930–2938.
- Weitz J. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022; 399(10333): 1383–1390.
- Shoamanesh A, Mundl H, Smith EE, et al. PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022; 400(10357): 997–1007.
- De Caterina R, Prisco D, Eikelboom JW. Factor XI inhibitors: cardiovascular perspectives. Eur Heart J. 2022 [Epub ahead of print].
- Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366(1): 9–19.
- Rao SV, Kirsch B, Bhatt DL, et al. PACIFIC AMI Investigators. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor xia inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation. 2022; 146(16): 1196–1206.
- Gue YX, Gorog DA, Lip GYH, et al. Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients? Circulation. 2022; 146(16): 1207–1209.
